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Abstract
Both acquired and congenital immunodeﬁciencies may be associated with increased susceptibility to invasive fungal infections (IFIs),
depending on the type of immune deﬁcit. IFIs frequently occur in patients with phagocytic and cellular immune defects, but are rarely
observed in those with humoral or complement deﬁcits. Among congenital immune disorders, chronic granulomatous disease and
hyper-IgE syndrome are most frequently associated with IFIs; variable susceptibility to fungal pathogens is also seen in patients with
severe combined immunodeﬁciency, X-linked hyper-IgM syndrome, Wiskott–Aldrich syndrome, DiGeorge syndrome, common variable
immunodeﬁciency, defects in the interferon-c–interleukin-12 axis, and myeloperoxidase deﬁciency. Aspergillus, Candida, Cryptococcus,
Histoplasma and other fungal genera are variably implicated in causing invasive infections in these patients. Prompt diagnosis of IFIs in
this patient population requires a high degree of suspicion, together with a knowledge of their clinical presentation and the limitations
of diagnostic modalities. Apart from administration of appropriate antifungal agents, successful management often requires the addition
of surgical intervention. Adjunctive immunotherapy may be considered, although this has not been systematically studied. Prophylactic
interferon-c and itraconazole administration have been shown to reduce the risk of IFIs in patients with chronic granulomatous disease;
however, the possibility of infections with azole-resistant organisms following long-term itraconazole prophylaxis should not be over-
looked.
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Introduction
Although fungi are often implicated in superﬁcial infections in
humans, they rarely cause invasive disease in healthy individu-
als; the latter tends to occur in patients with impaired
immune responses or in the presence of certain predisposing
factors. Among immunocompromised patients at risk for
invasive fungal infections (IFIs), those with congenital immuno-
deﬁciencies constitute a distinct group that has attracted sci-
entiﬁc interest over the last decades, in view of important
advances in immunology and mycology.
Congenital immunodeﬁciencies are hereditary disorders,
mainly single-gene abnormalities, that result in impaired
immune responses to a number of infectious stimuli. As a
consequence, patients may present with recurrent, pro-
tracted or severe infections caused by common pathogens,
or with infections caused by opportunistic organisms,
including fungi [1]. Despite the well-described orchestrated
interplay between innate and adaptive, humoral and cellular,
immunity, congenital immunodeﬁciencies are still classiﬁed
for practical purposes as those affecting mainly the humoral
or cellular component, the phagocytic component, and the
complement. A number of distinct, well-characterized immu-
nodeﬁciency syndromes have also been described that do
not clearly fall in one of the previous categories [1–3].
An effective host response against fungal pathogens
requires the coordinated contribution of both innate and
adaptive immunity. Neutrophils, mononuclear leukocytes and
dendritic cells are involved in fungal cell recognition and
damage. Both oxidative and non-oxidative mechanisms medi-
ate intracellular killing or extracellular damage of fungal ele-
ments. Oxidative fungal damage is achieved through reactive
oxygen intermediates generated by the enzymatic activity of
NADPH oxidase and nitric oxide synthase [4].
Over the last two decades, the adaptive immune response
against fungi has been thought to be regulated by the differ-
entiation of CD4+ T-cells towards T-helper type 1 (Th1) and
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T-helper type 2 (Th2) cells. The Th1 response is mediated
by the interleukin (IL)-12/interferon (IFN)-c axis, and stimu-
lates phagocytic activity, resulting in protection from fungal
infections. The Th2 response involves the production of IL-4
and IL-10, which downregulate the action of Th1 cytokines
[4,5]. Recently, a third subset of T-helper cells has been
described, the T-helper type 17 (Th17) cells, which produce
a distinct cytokine proﬁle, including IL-17A (IL-17), IL-17F,
IL-21 and IL-22. Th17 responses appear to be important for
protection against mucosal Candida infections [6]. Recent
studies, however, suggest that human host defences against
Aspergillus fumigatus rely more on Th1 than on Th17
responses [7]. The role of humoral responses in host
defence against fungal pathogens is less clearly deﬁned than
that of cellular immunity.
Consistent with the immune mechanisms involved in
human host defences against fungi, IFIs rarely occur in
patients with humoral or complement defects. Instead, they
can be observed with increased frequency in those with
phagocytic and cellular immune deﬁcits (Table 1) [8]. In the
present review, we will discuss IFIs in patients with congeni-
tal immune deﬁcits, beginning with chronic granulomatous
disease (CGD), which carries a higher risk of fungal infec-
tions than other immunodeﬁciencies.
CGD
This inherited disorder occurs with a prevalence of approx-
imately 1/250 000 live births, and is characterized by the
lack or signiﬁcant reduction of superoxide-generating
NADPH oxidase activity in phagocytic cells. In the absence
of superoxide anion and other reactive oxygen species, the
patient’s neutrophils are unable to kill catalase-producing
bacteria and fungi, including Staphylococcus aureus and A. fu-
migatus. They are also deﬁcient in forming neutrophil extra-
cellular traps, a distinct mechanism by which neutrophils
entrap and kill microorganisms [9]. This ineffective phagocy-
tic response in patients with CGD is associated with
chronic inﬂammation and formation of granulomas [10,11].
The lack of reactive oxygen derivatives was recently shown
to contribute to the hyperinﬂammatory phenotype through
a dysfunctional kynurenine pathway of tryptophan catabo-
lism [12]. Two-thirds of CGD patients have the X-linked
recessive form, which results from defects in the CYBB gene
encoding the gp91-phox subunit of the NADPH oxidase
complex. The remaining one-third have the autosomal
recessive form, which results from defects in the CYBA,
NCF-1 and NCF-2 genes, encoding subunits p22-phox, p47-
phox and p67-phox, respectively. Patients with autosomal
recessive CGD have a milder course than those with the
X-linked form [11]. Most IFIs among CGD patients are
caused by Aspergillus species and, to a lesser extent, by Can-
dida species and other fungal species [8].
Invasive aspergillosis (IA) in CGD patients
Data regarding the prevalence, clinical presentation and man-
agement of IA among individuals suffering from CGD origi-
nate from small series, case reports and two large patient
groups; the ﬁrst comprises 368 patients from the US CGD
registry, and the second 429 European patients [13,14].
When data from these two large cohorts are analysed, it
appears that Aspergillus species are the most commonly iso-
lated organisms from CGD patients with pneumonia (18–
41% of cases), the most common organisms isolated from
brain abscesses (38% of cases), and the ﬁrst or second most
common causes of osteomyelitis (22–35% of cases). Aspergil-
lus species are rarely implicated in cases of liver abscess,
lymphadenitis, arthritis and fungaemia among CGD patients.
In these and other series, IA was the most common cause of
death, accounting for at least one-third of fatalities [13–15].
Among the Aspergillus species causing invasive infection in
CGD patients, A. fumigatus is the most common, followed by
Aspergillus nidulans (teleomorph: Emericella nidulans). In a
cohort of 23 cases of IA in CGD patients, 17 were caused
by A. fumigatus and six by A. nidulans [16]. The relatively
increased frequency of A. nidulans infections in this patient
population contrasts with the fact that A. nidulans is an
uncommon pathogen in individuals with other types of
immunosuppression. Recently, infections caused by other
Emericella species, including Emericella quadrilineata, Emericella
rugulosa and E. nidulans var. echinulata, have been docu-
TABLE 1. Congenital immune defects and risk of invasive
fungal infection (IFI)
IFI unlikely Variable risk for IFI
Humoral Phagocytic
X-linked/autosomal
recessive
agammaglobulinaemia
Chronic granulomatous disease,
Myeloperoxidase deﬁciency
IgA deﬁciencya
Leukocyte adhesion deﬁciency,
Congenital neutropenias
Complement Cellular and combined
Classic, late or
alternative complement
defects
Severe combined immunodeﬁciency,
DiGeorge syndrome
Mannose-binding
lectin pathway
defects
X-linked hyper-IgM syndrome,
Wiskott–Aldrich syndrome
Other
Hyper-IgE syndrome, defects in
the IFN-c–IL-12 axis
IL, interleukin; IFN, interferon.
aIFIs have been observed in patients with common variable immunodeﬁciency,
possibly because of associated T-cell defects.
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mented in a small number of CGD patients. In most of these
cases, Emericella species had been previously identiﬁed incor-
rectly as A. nidulans by conventional methods [17]. Indeed,
there are subtle morphological differences among Emericella
species, which cannot be appreciated using light microscopy;
molecular techniques are required for correct identiﬁcation.
Finally, IA caused by Aspergillus ﬂavus has been recently
reported in a CGD patient [18].
IA may be the presenting manifestation of CGD, usually
occurring during the ﬁrst two decades of life of affected indi-
viduals. The site most commonly affected is the lung. Up to
one-third of patients may be asymptomatic, and IA can pres-
ent as a pulmonary inﬁltrate in routine chest radiographs. If
signs and symptoms of respiratory illness exist, these are not
speciﬁc. The differential diagnosis in this case should include
other causes of pulmonary infection commonly observed in
CGD patients, including S. aureus, Nocardia species, Burk-
holderia cepacia and non-Aspergillus fungal pathogens; mixed
infections may occur [13]. IA caused by A. fumigatus may also
primarily affect other sites, including the bones, brain, liver
and lymph nodes [18,19]. In contrast, primary extrapulmo-
nary sites are rarely observed for A. nidulans; infections
caused by this species usually originate from the lungs, and
appear to be more aggressive than those caused by A. fumig-
atus. Dissemination or local extension to the adjacent pleura,
chest wall and vertebrae frequently complicates A. nidulans
pulmonary infections [16,19]. Indeed, most of the osteomy-
elitis cases caused by A. nidulans in CGD patients involve the
ribs and vertebrae, as a result of contiguous spread of a pri-
mary lung lesion. This is not the case for A. fumigatus osteo-
myelitis, where at least half of the cases represent primary
infections of the cranium, humerus, femur and tibia [20].
The histological picture of IA lesions in CGD patients con-
trasts with that in neutropenic hosts, which is characterized
by angio-invasion, coagulative necrosis and paucity of neu-
trophils. By comparison, in CGD patients, discrete pyogra-
nulomatous lesions are observed, with an abundance of
neutrophils but intact hyphae, which are surrounded by his-
tiocytes and lymphocytes. Occasionally, giant cell formation
and foci of necrosis with microabscesses are found [19,21].
As for all opportunistic infections in immunocompromised
hosts, a high degree of clinical suspicion is important for
timely diagnosis of IA in CGD patients. High-resolution com-
puted tomography is the imaging study of choice in cases of
pulmonary infection. The so-called ‘classic’ radiological signs
of IA (halo and air-crescent sign) are not usually observed;
the ﬁndings are non-speciﬁc, including nodular lesions, perihi-
lar inﬁltrates, and segmental or lobar consolidation. Magnetic
resonance imaging has a role in the diagnosis of extrapulmonary
lesions, including brain abscesses [22]. Among non-invasive
diagnostic modalities, the serum galactomannan antigen assay
appears to have reduced sensitivity in CGD hosts, possibly
because of the lack of angio-invasion by fungal hyphae
[21,23]. In addition, false-positive results have been frequently
observed in young infants, and variable results have been
reported regarding the speciﬁcity of the galactomannan assay
in older children [24–27]. Aspergillus PCR and detection of
(1,3)-b-D-glucan have not yet been standardized or adequately
studied in CGD patients. Detection of fungal elements in
bronchoalveolar lavage ﬂuid and biopsy specimens may
provide signiﬁcant help in diagnosis [18,19].
The introduction of newer antifungal agents, including lipid
formulations of amphotericin B, the newer triazoles and ech-
inocandins, has broadened the therapeutic options for inva-
sive aspergillosis. Species identiﬁcation and in vitro
susceptibility testing may help to optimize treatment choices.
For example, A. nidulans appears to be less susceptible than
E. quadrilineata to amphotericin B and more susceptible to
caspofungin [17]. Azole resistance may be observed after
long-term azole prophylaxis in CGD patients (see below)
[28,29].
Besides antifungal agents, adjunctive therapy with inter-
feron (IFN)-c has been used in a number of cases [30,31].
Limited clinical data also suggest a role for granulocyte trans-
fusions from healthy donors in order to partially restore the
patients’ impaired phagocytic activity [32–34]. Finally, appro-
priate surgical debridement should not be delayed when
needed, particularly in cases of localized (liver abscess and
osteomyelitis) or aggressive lung infection [16].
The increased risk of infectious complications in CGD
patients has led to the introduction of prophylactic strategies
over the last two decades. Prophylactic subcutaneous admin-
istration of IFN-c, three times a week, was associated with a
reduction in the frequency of serious infections [35,36]. Daily
administration of itraconazole was well tolerated, and signiﬁ-
cantly reduced the frequency of severe IFIs among CGD
patients [37]. However, the possibility of breakthrough infec-
tions with azole-resistant Aspergillus strains following long-
term itraconazole prophylaxis should not be overlooked
[28,29]. Haematopoietic stem cell transplantation is currently
the only proven curative treatment for CGD in selected
patients; gene replacement therapy has been used experi-
mentally in patients lacking a suitable stem cell donor
[9,38,39].
Invasive candidiasis (IC) in CGD patients
IC is far less common than IA in this patient population. In
the US registry of 368 CGD patients, Candida species were
isolated from 20% of meningitis cases (most common cause),
11% of bacteraemia/fungaemia cases, and 7% of suppurative
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adenitis cases. However, they were rarely (2%) isolated from
patients with pneumonia or liver abscesses. IC was the cause
of death in 4% of patients [13]. In the European cohort of
429 patients, Candida species were recovered from 3% of
patients with septicaemia, 2% of those with pneumonia, <1%
of liver abscesses, and 0.5% of lymphadenitis cases [14].
IFIs caused by other species in CGD patients
Among other fungi causing infection in these patients, Paecil-
omyces species have been most frequently reported, being
the third most common cause of osteomyelitis in the US
registry (8% of cases) [13]. Paecilomyces variotii is the Paecil-
omyces species commonly implicated, whereas Paecilomyces li-
lacinus has been rarely isolated. Besides osteomyelitis,
Paecilomyces have been implicated in cases of pneumonia, soft
tissue infection and abscess formation [40–43].
A number of other species also have been reported to
cause IFIs in CGD patients, including members of the genera
Scedosporium, Trichosporon, Acremonium, Exophiala, Penicillium,
Rhizopus, Absidia, Fusarium, Microascus, Inonotus, Chrysosporium,
Cladophialophora, Neosartorya and Alternaria. In the majority of
these cases, IFIs have manifested as pneumonia, soft tissue
infection or bone infection [8,13,44–55].
Other Phagocytic Disorders
Myeloperoxidase deﬁciency
Myeloperoxidase deﬁciency has a prevalence of one in 2000–
4000 in Europe and the USA. Myeloperoxidase is produced
in neutrophils and monocytes and released into the phago-
somes, playing an adjunctive role in phagocytosis; its absence
is associated with impaired killing of Candida species in vitro
and in animal models. The vast majority of myeloperoxidase-
deﬁcient individuals are, however, asymptomatic [3,56,57].
The susceptibility to invasive Candida infections appears to
be increased in the presence of other predisposing condi-
tions, such as diabetes. Overall, IFIs occur in fewer than 5%
of myeloperoxidase-deﬁcient individuals. IC in these patients
may present as candidaemia, disseminated infection, pneumo-
nia, osteomyelitis, meningitis or liver abscess. Antifungal pro-
phylaxis is not indicated [3,8,57–60].
Leukocyte adhesion deﬁciency (LAD)
LAD comprises a group of rare inherited disorders of leuko-
cyte rolling, adhesion and cytoskeletal regulation [1].
Although older reviews concerning LAD patients suggested
increased susceptibility to infections caused by Candida and
Aspergillus species, there have been very few case reports of
IFIs in these patients in recent years [3,8].
Congenital neutropenias
Patients with cyclic neutropenia are at low risk of IFIs, owing
to the short duration of the neutropenia phase and the bone
marrow’s residual capacity to produce neutrophils when
stimulated. Similarly, reports of IFIs among patients with
other forms of congenital neutropenia (Kostmann syndrome,
and neutropenias associated with metabolic or immunological
disorders) are scarce in the literature [3,61,62].
Cellular and Combined Immunodeﬁciencies
Severe combined immunodeﬁciency (SCID)
An expanding group of distinct congenital immune defects,
affecting both T-cell and B-cell function, is represented under
the term SCID [1,2]. Increased susceptibility to fungal infec-
tions is observed among these patients. Candida and Aspergil-
lus are the genera most commonly implicated in previous
reports. IC may manifest as meningitis or pneumonia [63,64];
aspergillosis may present as lung infection [65,66]. Isolated
cases involving other fungi, namely Acremonium and Pichia
species, have also been published [67,68].
DiGeorge syndrome
Patients with DiGeorge syndrome have variably decreased
T-cell numbers and, in the case of signiﬁcant thymic hypopla-
sia or aplasia, they present with a SCID-like picture [1].
There are few reports of IA in these patients; it may mani-
fest as lung or disseminated infection [69,70].
X-linked hyper-IgM syndrome
Patients with X-linked hyper-IgM syndrome have a combined
cellular and humoral defect, and should be distinguished from
those with the autosomal hyper-IgM syndrome, where cellu-
lar immunity is not affected [71]. Increased susceptibility to
fungal infections has been observed in these patients, with
Candida, Cryptococcus and Histoplasma being the genera most
commonly implicated. IC may present as a bloodstream
infection, and cryptococcosis as central nervous system, lym-
phonodular, bloodstream or disseminated disease [71–73].
Histoplasmosis may manifest as pneumonia, hepatitis or dis-
seminated disease, involving the lungs, bone marrow and
bloodstream [71,74].
Wiskott–Aldrich syndrome
The clinical course and infectious complications in patients
with Wiskott–Aldrich syndrome are more severe in those
with undetectable or truncated Wiskott–Aldrich syndrome
protein (WASP) than in those with normal or reduced
amounts of full-length mutated WASP. IFIs appear to affect
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exclusively WASP-negative patients; in a series of 23 WASP-
negative individuals, nine episodes of IC and three of asper-
gillosis were observed [1,75].
Humoral Immunodeﬁciencies
Common variable immunodeﬁciency (CVID)
Patients suffering from humoral immunodeﬁciencies (such as
X-linked or autosomal recessive agammaglobulinaemia and IgA
deﬁciency) do not generally exhibit increased susceptibility to
fungal infections. CVID, however, comprises a heterogeneous
group of disorders, which often include abnormalities in T-cell
phenotype and function, secretion of cytokines, or T-cell
receptor signalling events [1,64,76]. A number of case reports
of IFIs in CVID patients have been published, including histo-
plasmosis (meningitis and disseminated infection), aspergillosis
(lung infection and liver abscess) and disseminated infection
caused by Penicillium marneffei [77–82].
Other Congenital Immunodeﬁciencies
Hyper-IgE syndrome (HIES)
HIES is characterized by elevated IgE and eosinophilia, eczema,
and recurrent skin and pulmonary infections. The autosomal
dominant (AD) form of HIES is further characterized by con-
nective tissue and skeletal abnormalities (coarse facial features
and retention of primary teeth) as well as disordered inﬂam-
mation [83,84]. Recently, AD HIES was shown to result from
mutations in the signal transducer and activator of transcrip-
tion (STAT) 3 gene [85]. HIES patients display a distorted Th1/
Th2 cytokine production pattern favouring Th2 responses,
which is manifested by decreased production of IFN-c in
response to infectious stimuli (S. aureus and Candida albicans)
[86–88]. In addition, a profound reduction in the number of
Th17 cells has been recently described, and proposed to be
one of the diagnostic features for HIES [89,90].
Increased susceptibility to IFIs has been reported for HIES
patients, including yeast infections caused mainly by Candida
species (bloodstream infection, disseminated disease, visceral
candidiasis, endocarditis, and endophthalmitis) [91–94], Cryp-
tococcus neoformans (meningitis and gastrointestinal disease)
[95,96] and Histoplasma capsulatum (ileocecal histoplasmosis)
[97]. Aspergillus species may also affect HIES patients, usually
by colonizing pre-existing pneumatocoeles and forming
aspergillomas. Occasionally, however, local invasion of the
lung parenchyma may occur, and this can rarely be followed
by dissemination to the central nervous system and forma-
tion of mycotic aneurysms [98–101]. In a series of 64 AD
HIES patients, 28.1% developed mould infections caused by
Aspergillus (n = 16) or Scedosporium (n = 2) species. The
attributed mortality was 17%. Fungicidal activity and chemo-
taxis were not different between neutrophils from AD HIES
patients and those from healthy controls. IFIs in HIES
patients commonly occurred in their fourth decade of life.
This late-onset risk of IFI despite normal phagocytic function
was associated with bronchiectasis/pneumatocoeles, and was
probably related to the role of STAT3 in lung epithelial
homeostasis and defence [102].
Defects in the IFN-c–IL-12 axis
A number of distinct defects in components of IL-12, the IL-
12 receptor, IFN-c receptor or STAT1 have been described
[1,3]. Affected patients have been reported to develop dis-
seminated infections caused by endemic fungi (H. capsulatum
and Paracoccidioides brasiliensis) [103,104].
Conclusions
Patients with congenital phagocytic, cellular or combined
immune defects exhibit increased susceptibility to IFIs. CGD
and AD HIES are associated with the highest incidence of
IFIs among congenital immunodeﬁciencies. Knowledge of the
spectrum of implicated fungal pathogens and clinical presen-
tation of IFIs in these patients, together with a high degree
of suspicion, are essential for timely diagnosis. Uncommon
species isolated from these individuals should not readily be
discarded as contaminants. The limitations of newer diagnos-
tic modalities (e.g. galactomannan antigen detection in CGD
patients) should be taken into account. Administration of
antifungal agents alone may not sufﬁce for successful manage-
ment of IFIs in patients with congenital immunodeﬁciencies.
Surgical intervention is often necessary; adjunctive immuno-
therapy may be considered, although this has not been sys-
tematically studied. Prophylaxis with IFN-c and itraconazole
is recommended for CGD patients.
Transparency Declaration
The author has no conﬂicts of interest.
References
1. Kumar A, Teuber SS, Gershwin ME. Current perspectives on pri-
mary immunodeﬁciency diseases. Clin Dev Immunol 2006; 13: 223–
259.
CMI Antachopoulos Fungal infections in congenital immunodeﬁciencies 1339
ª2010 The Author
Clinical Microbiology and Infection ª2010 European Society of Clinical Microbiology and Infectious Diseases, CMI, 16, 1335–1342
2. Buckley RH. Primary immunodeﬁciency diseases due to defects in
lymphocytes. N Engl J Med 2000; 343: 1313–1324.
3. Lekstrom-Himes JA, Gallin JI. Immunodeﬁciency diseases caused by
defects in phagocytes. N Engl J Med 2000; 343: 1703–1714.
4. Romani L. Immunity to fungal infections. Nat Rev Immunol 2004; 4:
1–23.
5. Mencacci A, Cenci E, Bacci A, Montagnoli C, Bistoni F, Romani L.
Cytokines in candidiasis and aspergillosis. Curr Pharm Biotechnol 2000;
1: 235–251.
6. van de Veerdonk FL, Gresnigt MS, Kullberg BJ, van der Meer JWM,
Joosten LAB, Netea MG. Th17 responses and host defense against
microorganisms: an overview. BMB Rep 2009; 42: 776–787.
7. Chai LY, van de Veerdonk F, Marijnissen RJ et al. Anti-Aspergillus
human host defence relies on type 1 T helper (Th1), rather than
type 17 T helper (Th17), cellular immunity. Immunology 2010; 130:
46–54.
8. Antachopoulos C, Walsh TJ, Roilides E. Fungal infections in primary
immunodeﬁciencies. Eur J Pediatr 2007; 166: 1099–1117.
9. Bianchi M, Hakkim A, Brinkmann V et al. Restoration of NET forma-
tion by gene therapy in CGD controls aspergillosis. Blood 2009; 114:
2619–2622.
10. Assari T. Chronic granulomatous disease; fundamental stages in our
understanding of CGD. Med Immunol 2006; 5: 4.
11. Heyworth PG, Cross AR, Curnutte JT. Chronic granulomatous dis-
ease. Curr Opin Immunol 2003; 15: 578–584.
12. Romani L, Fallarino F, De Luca A et al. Defective tryptophan catabo-
lism underlies inﬂammation in mouse chronic granulomatous disease.
Nature 2008; 451: 211–215.
13. Winkelstein JA, Marino MC, Johnston RB et al. Chronic granuloma-
tous disease. Report on a national registry of 368 patients. Medicine
(Baltimore) 2000; 79: 155–169.
14. van den Berg JM, van Koppen E, Ahlin A et al. Chronic granuloma-
tous disease: the European experience. PLoS ONE 2009; 4: e5234.
15. Liese J, Kloos S, Jendrossek V et al. Long-term follow-up and out-
come of 39 patients with chronic granulomatous disease. J Pediatr
2000; 137: 687–693.
16. Segal BH, DeCarlo ES, Kwon-Chung KJ, Malech HL, Gallin JI, Hol-
land SM. Aspergillus nidulans infection in chronic granulomatous dis-
ease. Medicine (Baltimore) 1998; 77: 345–354.
17. Verweij PE, Varga J, Houbraken J et al. Emericella quadrilineata as
cause of invasive aspergillosis. Emerg Infect Dis 2008; 14: 566–572.
18. Mamishi S, Parvaneh N, Salavati A, Abdollahzadeh S, Yeganeh M.
Invasive aspergillosis in chronic granulomatous disease: report of 7
cases. Eur J Pediatr 2007; 166: 83–84.
19. Almyroudis NG, Holland SM, Segal BH. Invasive aspergillosis in pri-
mary immunodeﬁciencies. Med Mycol 2005; 43 (suppl 1): S247–S259.
20. Dotis J, Roilides E. Osteomyelitis due to Aspergillus spp. in patients
with chronic granulomatous disease: comparison of Aspergillus nidu-
lans and Aspergillus fumigatus. Int J Infect Dis 2004; 8: 103–110.
21. Dennis CG, Greco WR, Brun Y et al. Effect of amphotericin B and
micafungin combination on survival, histopathology, and fungal bur-
den in experimental aspergillosis in the p47phox–/– mouse model of
chronic granulomatous disease. Antimicrob Agents Chemother 2006;
50: 422–427.
22. Thomas KE, Owens CM, Veys PA, Novelli V, Costoli V. The radio-
logical spectrum of invasive aspergillosis in children: a 10-year
review. Pediatr Radiol 2003; 33: 453–460.
23. Verweij PE, Weemaes CM, Curfs JH, Bretagne S, Meis JF. Failure to
detect circulating Aspergillus markers in a patient with chronic granu-
lomatous disease and invasive aspergillosis. J Clin Microbiol 2000; 38:
3900–3901.
24. Siemann M, Koch-Dorﬂer M, Gaude M. False-positive results in pre-
mature infants with the Platelia Aspergillus sandwich enzyme-linked
immunosorbent assay. Mycoses 1998; 41: 373–377.
25. Roilides E. Early diagnosis of invasive aspergillosis in infants and chil-
dren. Med Mycol 2006; 44 (suppl): S199–S205.
26. Steinbach WJ, Addison RM, McLaughlin L et al. Prospective Asper-
gillus galactomannan antigen testing in pediatric hematopoietic
stem cell transplant recipients. Pediatr Infect Dis J 2007; 26: 558–
564.
27. Castagnola E, Furfaro E, Caviglia I et al. Performance of the galacto-
mannan antigen detection test in the diagnosis of invasive aspergillo-
sis in children with cancer or undergoing haemopoietic stem cell
transplantation. Clin Microbiol Infect 2010; 16: 1197–1203.
28. Verweij PE, Mellado E, Melchers WJ. Multiple-triazole-resistant
aspergillosis. N Engl J Med 2007; 356: 1481–1483.
29. Hodiamont CJ, Dolman KM, Ten Berge IJ, Melchers WJ, Verweij PE,
Pajkrt D. Multiple-azole-resistant Aspergillus fumigatus osteomyelitis
in a patient with chronic granulomatous disease successfully treated
with long-term oral posaconazole and surgery. Med Mycol 2009; 47:
210–220.
30. Al-Tawﬁq JA, Al-Abdely HM. Vertebral osteomyelitis due to Asper-
gillus fumigatus in a patient with chronic granulomatous disease suc-
cessfully treated with antifungal agents and interferon-gamma. Med
Mycol 2010; 48: 537–541.
31. Saulsbury FT. Successful treatment of aspergillus brain abscess with
itraconazole and interferon-gamma in a patient with chronic granu-
lomatous disease. Clin Infect Dis 2001; 32: E137–E139.
32. Briones MA, Josephson CD, Hillyer CD. Granulocyte transfusion:
revisited. Curr Hematol Rep 2003; 2: 522–527.
33. Ikinciogullari A, Dogu F, Solaz N et al. Granulocyte transfusions in
children with chronic granulomatous disease and invasive aspergillo-
sis. Ther Apher Dial 2005; 9: 137–141.
34. Raj R, Kamath SR, Ranjit S, Shankar N, Lakshmanan V. Granulocyte
transfusion in children. Indian Pediatr 2009; 46: 516–518.
35. The International Chronic Granulomatous Disease Cooperative
Study Group. A controlled trial of interferon gamma to prevent
infection in chronic granulomatous disease. The International
Chronic Granulomatous Disease Cooperative Study Group. N Engl J
Med 1991; 324: 509–516.
36. Marciano BE, Wesley R, De Carlo ES et al. Long-term interferon-
gamma therapy for patients with chronic granulomatous disease. Clin
Infect Dis 2004; 39: 692–699.
37. Gallin JI, Alling DW, Malech HL et al. Itraconazole to prevent fungal
infections in chronic granulomatous disease. N Engl J Med 2003; 348:
2416–2422.
38. Reichenbach J, Van de Velde H, De Rycke M et al. First successful
bone marrow transplantation for X-linked chronic granulomatous
disease by using preimplantation female gender typing and HLA
matching. Pediatrics 2008; 122: e778–e782.
39. Seger RA. Modern management of chronic granulomatous disease.
Br J Haematol 2008; 140: 255–266.
40. Cohen-Abbo A, Edwards KM. Multifocal osteomyelitis caused by
Paecilomyces variotii in a patient with chronic granulomatous disease.
Infection 1995; 23: 55–57.
41. Wang SM, Shieh CC, Liu CC. Successful treatment of Paecilomyces
variotii splenic abscesses: a rare complication in a previously unrecog-
nized chronic granulomatous disease child. Diagn Microbiol Infect Dis
2005; 53: 149–152.
42. Williamson PR, Kwon-Chung KJ, Gallin JI. Successful treatment of
Paecilomyces variotii infection in a patient with chronic granulomatous
disease and a review of Paecilomyces species infections. Clin Infect Dis
1992; 14: 1023–1026.
43. Silliman CC, Lawellin DW, Lohr JA, Rodgers BM, Donowitz LG. Pae-
cilomyces lilacinus infection in a child with chronic granulomatous dis-
ease. J Infect 1992; 24: 191–195.
44. Phillips P, Forbes JC, Speert DP. Disseminated infection with Pseudal-
lescheria boydii in a patient with chronic granulomatous disease:
1340 Clinical Microbiology and Infection, Volume 16 Number 9, September 2010 CMI
ª2010 The Author
Clinical Microbiology and Infection ª2010 European Society of Clinical Microbiology and Infectious Diseases, CMI, 16, 1335–1342
response to gamma-interferon plus antifungal chemotherapy. Pediatr
Infect Dis J 1991; 10: 536–539.
45. Piwoz JA, Stadtmauer GJ, Bottone EJ, Weitzman I, Shlasko E, Cum-
mingham-Rundles C. Trichosporon inkin lung abscesses presenting as a
penetrating chest wall mass. Pediatr Infect Dis J 2000; 19: 1025–1027.
46. Boltansky H, Kwon-Chung KJ, Macher AM, Gallin JI. Acremonium
strictum-related pulmonary infection in a patient with chronic granu-
lomatous disease. J Infect Dis 1984; 149: 653.
47. Kenney RT, Kwon-Chung KJ, Waytes AT et al. Successful treatment
of systemic Exophiala dermatitidis infection in a patient with chronic
granulomatous disease. Clin Infect Dis 1992; 14: 235–242.
48. Santos PE, Piontelli E, Shea YR et al. Penicillium piceum infection: diag-
nosis and successful treatment in chronic granulomatous disease.
Med Mycol 2006; 44: 749–753.
49. Abinun M, Wright C, Gould K, Flood TJ, Cassidy J. Absidia cor-
ymbifera in a patient with chronic granulomatous disease. Pediatr
Infect Dis 2007; 26: 1167–1168.
50. Marques AR, Kwon-Chung KJ, Holland SM, Turner ML, Gallin JI.
Suppurative cutaneous granulomata caused by Microascus cinereus in
a patient with chronic granulomatous disease. Clin Infect Dis 1995;
20: 110–114.
51. Sutton DA, Thompson EH, Rinaldi MG et al. Identiﬁcation and ﬁrst
report of Inonotus (Phellinus) tropicalis as an etiologic agent in a
patient with chronic granulomatous disease. J Clin Microbiol 2005; 43:
982–987.
52. Roilides E, Sigler L, Bibashi E, Katsifa H, Flaris N, Panteliadis C. Dis-
seminated infection due to Chrysosporium zonatum in a patient with
chronic granulomatous disease and review of non-Aspergillus fungal
infections in patients with this disease. J Clin Microbiol 1999; 37: 18–
25.
53. Shigemura T, Agematsu K, Yamazaki T et al. Femoral osteomyelitis
due to Cladophialophora arxii in a patient with chronic granuloma-
tous disease. Infection 2009; 37: 469–473.
54. Vinh DC, Shea YR, Sugui JA et al. Invasive aspergillosis due to Neo-
sartorya udagawae. Clin Infect Dis 2009; 49: 102–111.
55. Hipolito E, Faria E, Alves AF et al. Alternaria infectoria brain abscess
in a child with chronic granulomatous disease. Eur J Clin Microbiol
Infect Dis 2009; 28: 377–380.
56. Cramer R, Soranzo MR, Dri P et al. Incidence of myeloperoxidase
deﬁciency in an area of northern Italy: histochemical, biochemical
and functional studies. Br J Haematol 1982; 51: 81–87.
57. Parry MF, Root RK, Metcalf JA, Delaney KK, Kaplow LS, Richar WJ.
Myeloperoxidase deﬁciency: prevalence and clinical signiﬁcance. Ann
Intern Med 1981; 95: 293–301.
58. Cech P, Stalder H, Widmann JJ, Rohner A, Miescher PA. Leukocyte
myeloperoxidase deﬁciency and diabetes mellitus associated with
Candida albicans liver abscess. Am J Med 1979; 66: 149–153.
59. Chiang AK, Chan GC, Ma SK, Ng YK, Ha SY, Lau YL. Disseminated
fungal infection associated with myeloperoxidase deﬁciency in a pre-
mature neonate. Pediatr Infect Dis J 2000; 19: 1027–1029.
60. Kalinski T, Jentsch-Ullrich K, Fill S, Ko¨nig B, Costa SD, Roessner A.
Lethal candida sepsis associated with myeloperoxidase deﬁciency
and pre-eclampsia. APMIS 2007; 115: 875–880.
61. Zeidler C. Congenital neutropenias. Hematology 2005; 10 (suppl 1):
306–311.
62. Zeidler C, Welte K, Barak Y et al. Stem cell transplantation in
patients with severe congenital neutropenia without evidence of leu-
kemic transformation. Blood 2000; 95: 1195–1198.
63. Smego RA Jr, Devoe PW, Sampson HA, Perfect JR, Wilfert CM,
Buckley RH. Candida meningitis in two children with severe com-
bined immunodeﬁciency. J Pediatr 1984; 104: 902–904.
64. Yin EZ, Frush DP, Donnelly LF, Buckley RH. Primary immunodeﬁ-
ciency disorders in pediatric patients: clinical features and imaging
ﬁndings. AJR Am J Roentgenol 2001; 176: 1541–1552.
65. Yoshihara T, Morimoto A, Nakauchi S et al. Successful transplanta-
tion of haploidentical CD34+ selected bone marrow cells for an
infantile case of severe combined immunodeﬁciency with Aspergillus
pneumonia. Pediatr Hematol Oncol 2002; 19: 439–443.
66. Kobayashi S, Murayama S, Tatsuzawa O et al. X-linked severe com-
bined immunodeﬁciency (X-SCID) with high blood levels of immuno-
globulins and Aspergillus pneumonia successfully treated with
micafangin followed by unrelated cord blood stem cell transplanta-
tion. Eur J Pediatr 2007; 166: 207–210.
67. Lau YL, Yuen KY, Lee CW, Chan CF. Invasive Acremonium falciforme
infection in a patient with severe combined immunodeﬁciency. Clin
Infect Dis 1995; 20: 197–198.
68. Bakir M, Cerikcioglu N, Tirtir A, Berrak S, Ozek E, Canpolat C. Pi-
chia anomala fungaemia in immunocompromised children. Mycoses
2004; 47: 231–235.
69. Marcinkowski M, Bauer K, Stoltenburg-Didinger G, Vogel M, Vers-
mold H. Fatal aspergillosis with brain abscesses in a neonate with
DiGeorge syndrome. Pediatr Infect Dis J 2000; 19: 1214–1216.
70. Sergi C, Serpi M, Muller-Navia J et al. CATCH 22 syndrome: report
of 7 infants with follow-up data and review of the recent advance-
ments in the genetic knowledge of the locus 22q11. Pathologica
1999; 91: 166–172.
71. Winkelstein JA, Marino MC, Ochs H et al. The X-linked hyper-IgM
syndrome: clinical and immunologic features of 79 patients. Medicine
(Baltimore) 2003; 82: 373–384.
72. Lee MY, Chung JH, Shin JH et al. Lymphonodular cryptococcosis
diagnosed by ﬁne needle aspiration cytology in hyper-IgM syndrome.
A case report. Acta Cytol 2001; 45: 241–244.
73. Iseki M, Anzo M, Yamashita N, Matsuo N. Hyper-IgM immunodeﬁciency
with disseminated cryptococcosis. Acta Paediatr 1994; 83: 780–782.
74. Hostoffer RW, Berger M, Clark HT, Schreiber JR. Disseminated Hi-
stoplasma capsulatum in a patient with hyper IgM immunodeﬁciency.
Pediatrics 1994; 94: 234–236.
75. Imai K, Morio T, Zhu Y et al. Clinical course of patients with WASP
gene mutations. Blood 2004; 103: 456–464.
76. Salzer U, Grimbacher B. Common variable immunodeﬁciency: the
power of co-stimulation. Semin Immunol 2006; 18: 337–346.
77. Kane S, Brasitus T. Histoplasmosis capsulatum as a cause of lower
gastrointestinal bleeding in common variable immunodeﬁciency. Dig
Dis Sci 2000; 45: 2133–2135.
78. Rachid A, Rezende LS, de Moura SF, Loffy PC, Magalhaes FL. A case
study of disseminated histoplasmosis linked to common variable
immunodeﬁciency. Braz J Infect Dis 2003; 7: 268–272.
79. Couch JR, Romyg DA. Histoplasma meningitis with common variable
hypogammaglobulinemia. Neurol Neurocir Psiquiatr 1977; 18: 403–412.
80. Tinelli M, Zambelli A, Cavanna C, Michelone G. Pulmonary aspergil-
losis in a case of humoral immunodeﬁciency. Microbiologica 1987; 10:
235–240.
81. Trachana M, Roilides E, Gompakis N, Kanellopoulou K, Mpantouraki
M, Kanakoudi-Tsakalidou F. Case report. Hepatic abscesses due to
Aspergillus terreus in an immunodeﬁcient child. Mycoses 2001; 44:
415–418.
82. Lin WC, Dai YS, Tsai MJ, Huang LM, Chiang BL. Systemic Penicillium
marneffei infection in a child with common variable immunodeﬁ-
ciency. J Formos Med Assoc 1998; 97: 780–783.
83. Minegishi Y. Hyper-IgE syndrome. Curr Opin Immunol 2009; 21: 487–
492.
84. Heimall J, Freeman A, Holland SM. Pathogenesis of hyper IgE syn-
drome. Clin Rev Allergy Immunol 2010; 38: 32–38.
85. Holland SM, DeLeo FR, Elloumi HZ et al. STAT3 mutations in the
hyper-IgE syndrome. N Engl J Med 2007; 18: 1608–1619.
86. Borges WG, Augustine NH, Hill HR. Defective interleukin-12/inter-
feron-gamma pathway in patients with hyperimmunoglobulinemia E
syndrome. J Pediatr 2000; 136: 176–180.
CMI Antachopoulos Fungal infections in congenital immunodeﬁciencies 1341
ª2010 The Author
Clinical Microbiology and Infection ª2010 European Society of Clinical Microbiology and Infectious Diseases, CMI, 16, 1335–1342
87. Chehimi J, Elder M, Greene J et al. Cytokine and chemokine dysre-
gulation in hyper-IgE syndrome. Clin Immunol 2001; 100: 49–56.
88. Netea MG, Kullberg BJ, van der Meer JW. Severely impaired IL-12/
IL-18/IFNgamma axis in patients with hyper IgE syndrome. Eur J Clin
Invest 2005; 35: 718–721.
89. Ma CS, Chew GY, Simpson N et al. Deﬁciency of Th17 cells in
hyper IgE syndrome due to mutations in STAT3. J Exp Med 2008;
205: 1551–1557.
90. Woellner C, Gertz EM, Scha¨ffer AA et al. Mutations in STAT3 and
diagnostic guidelines for hyper-IgE syndrome. J Allergy Clin Immunol
2010; 125: 424–432.
91. Grimbacher B, Holland SM, Gallin JI et al. Hyper-IgE syndrome with
recurrent infections—an autosomal dominant multisystem disorder.
N Engl J Med 1999; 340: 692–702.
92. Haslett RS, Moriarty AP, Vijayadurai P, McGalliard JN, Chandna A.
Candida endophthalmitis in Job syndrome. Arch Ophthalmol 1996;
114: 617–618.
93. Yates AB, Mehrotra D, Mofﬁtt JE. Candida endocarditis in a child
with hyperimmunoglobulinemia E syndrome. J Allergy Clin Immunol
1997; 99: 770–772.
94. Yilmaz E. Disseminated pulmonary candidiasis complicating hyperim-
munoglobulin E (Job’s) syndrome. J Thorac Imaging 2004; 19: 48–51.
95. Hutto JO, Bryan CS, Greene FL, White CJ, Gallin JI. Cryptococcosis
of the colon resembling Crohn’s disease in a patient with the hyper-
immunoglobulinemia E-recurrent infection (Job’s) syndrome. Gastro-
enterology 1988; 94: 808–812.
96. Garty BZ, Wolach B, Ashkenazi S, Weismart Y, Rachmel A, Nitzan
M. Cryptococcal meningitis in a child with hyperimmunoglobulin E
syndrome. Pediatr Allergy Immunol 1995; 6: 175–177.
97. Steiner SJ, Kleiman MB, Corkins MR, Christenson JC, Wheat LJ. Ile-
ocecal histoplasmosis simulating Crohn disease in a patient with hy-
perimmunoglobulin E syndrome. Pediatr Infect Dis J 2009; 28: 744–
746.
98. Hall RA, Salhany KE, Lebel E, Bavaria JE, Kaiser LR. Fungal pulmo-
nary abscess in an adult secondary to hyperimmunoglobulin E (Job’s)
syndrome. Ann Thorac Surg 1995; 59: 759–761.
99. Santambrogio L, Nosotti M, Pavoni G, Harte M, Pietogrande MC.
Pneumatocele complicated by fungal lung abscess in Job’s syndrome.
Successful lobectomy with the aid of videothoracoscopy. Scand Car-
diovasc J 1997; 31: 177–179.
100. van der Meer JW, Bont L, Verhage J. Aspergillus infection in patients
with hyperimmunoglobulin E syndrome. Clin Infect Dis 1998; 27:
1337.
101. Wolach B, Eliakim A, Gottesman G, Yellin A. Pulmonary aspergillosis
in a child with hyperimmunoglobulin E syndrome. Clin Infect Dis
1998; 26: 204–205.
102. Vinh DC, Sugui JA, Hsu AP, Freeman AF, Holland SM. Invasive fungal
disease in autosomal-dominant hyper-IgE syndrome. J Allergy Clin
Immunol 2010; 125: 1389–1390.
103. Zerbe CS, Holland SM. Disseminated histoplasmosis in persons with
interferon-gamma receptor 1 deﬁciency. Clin Infect Dis 2005; 41:
e38–e41.
104. Moraes-Vasconcelos D, Grumach AS, Yamaguti A et al. Paracoccidio-
ides brasiliensis disseminated disease in a patient with inherited deﬁ-
ciency in the beta1 subunit of the interleukin (IL)-12/IL-23 receptor.
Clin Infect Dis 2005; 41: e31–e37.
1342 Clinical Microbiology and Infection, Volume 16 Number 9, September 2010 CMI
ª2010 The Author
Clinical Microbiology and Infection ª2010 European Society of Clinical Microbiology and Infectious Diseases, CMI, 16, 1335–1342
